###### Strengths and limitations of this study

-   We conducted a comprehensive literature search and strictly adhered to the projected methodology.

-   We identified a lack of quality in non-randomised controlled clinical trials reporting patient-reported outcomes, analysed the cause and suggested possible improvements in designing studies in the future.

-   The analysis is confined to a single disease and a specific treatment and conclusions drawn from its results may not be generalisable to other diseases and treatments.

-   The limits for the inclusion of studies are arbitrarily set.

Introduction {#s1}
============

The present paper reports a workup of a previously published systematic review.[@R1] It may be regarded as a methodological supplement adding information on a subset of excluded studies. We have compared permanent interstitial low-dose rate brachytherapy, with radical prostatectomy, external beam radiotherapy and 'no primary therapy' in patients with localised prostate cancer categorised as T1 to T2. We used the term 'no primary therapy' to accommodate different types of observation including active surveillance, watchful waiting and observing without a distinctive management. As a result, we included one randomised controlled trial (RCT) and 30 non-randomised controlled clinical trials (CCT). The primary outcome was overall survival. The secondary outcomes were clinically defined disease-free survival, biochemical recurrence-free survival, physician-reported severe adverse events and patient-reported outcomes (PROs) such as function and bother scores as well as generic and disease-related health-related quality of life. We concluded that the current evidence is insufficient to allow a definitive conclusion about overall survival. Radical prostatectomy and external beam radiotherapy can severely affect the structural integrity of neighbouring organs and their functions and can also cause considerable long-term impairment of health-related quality of life. With a view of expecting similar survival but a tremendous difference of adverse events between treatment alternatives, valid data on health-related quality of life could tip the balance. At the least, we assume that shared decision-making and consideration of patients' preferences in searching for the best individual treatment would rely on information on the health-related quality-of-life data. Of the 30 included non-randomised studies, 13 studies reported PROs, that is, only the patients provided the information.[@R2] During the study selection process, we experienced that we excluded another 50 non-randomised PRO studies. We found it a pity that we could not use the data. We had the impression that a considerable number of studies were excluded because of a lack in the quality of reporting. Therefore, we wanted to summarise the reasons for excluding those PRO studies and make the authors of PRO studies aware of some basic requirements for reporting of comparative PRO data to achieve higher acceptance in the scientific community. The importance of reporting PRO has been addressed by the Consolidated Standards of Reporting Trials (CONSORT) group[@R3] which recently published a PRO extension to their acclaimed previous statement.[@R4] It may be wise to build a PRO extension to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement[@R5] that addresses specific issues of observational studies.

The first aim of this study was to assess whether the excluded studies met the basic inclusion criteria using the PICO framework. The second aim was to ensure whether the excluded studies met the requirements to contain high risk of bias.

Materials and methods {#s2}
=====================

Study inclusion criteria {#s2a}
------------------------

We defined the inclusion criteria according to the PICO framework that should include four essential constituents, that is, the type of participants (P), intervention (I), comparator (C) and outcome (O).[@R6] The four PICO items can be supplemented by timing (T) and setting (S), two other important features of a systematic review, to create the so-called PICOTS typology.[@R7] A further extension embraces the study design (SD) to complete all major items of a search strategy (PICOTS-SD).[@R8]

### Population {#s2a1}

#### Initial and present publication {#s2a1a}

Localised prostate cancer is defined by the categories T1 to T2 of the tumour-node-metastasis staging system[@R9] if combined with the absence of regional lymph node metastasis and distant metastasis.

### Intervention {#s2a2}

#### Initial and present publication {#s2a2a}

Brachytherapy[@R10] is short-distance radiotherapy placing radiation sources with different duration and rates of dose delivery in or near tumours.[@R11] Permanent interstitial low-dose rate brachytherapy means implanting of low-energy radioactive sources emitting radiation, which are contained in titanium pellets of the size of rice grains called seeds.[@R12]

### Comparator {#s2a3}

#### Initial and present publication {#s2a3a}

The European Association of Urology suggested three different treatment concepts for localised prostate cancer in addition to permanent interstitial low-dose rate brachytherapy[@R10]: radical prostatectomy, external beam radiotherapy and different types of observation including active surveillance, watchful waiting and observing without distinctive management.

### Outcome {#s2a4}

#### Initial publication {#s2a4a}

Overall survival, cancer-specific survival, disease-free survival, biochemical recurrence-free survival, severe adverse events and PROs. PROs comprised function and bother scores as well as generic and disease-related health-related quality of life.

#### Present publication {#s2a4b}

Fulfilment of basic inclusion criteria according to a PICO framework by the excluded CCT. Accomplishment of requirements to contain superimposed risk of bias in addition to the high risk of bias caused by the lack of randomisation framework by the excluded CCT.

### Timing {#s2a5}

#### Initial and present publication {#s2a5a}

We did not set limits on the length of the observation period.

### Setting {#s2a6}

#### Initial and present publication {#s2a6a}

We did not set limits on the setting such as type of country, year of recruitment or level of healthcare.

### Study design {#s2a7}

#### Initial publication {#s2a7a}

We included RCT and CCT evaluating permanent interstitial low-dose rate brachytherapy as monotherapy in patients with localised prostate cancer. The proportion of relevant patients was required to be at least 80% of the study population and the response rate of questionnaires was expected to be at least 70%. For CCT to be included, comparable baseline characteristics between treatment groups or adjustment for imbalances of these data were required. Limits on year of publication or language were not applied.

#### Present publication {#s2a7b}

We included specifically the CCT that were excluded in the initial publication.

Search strategy {#s2b}
---------------

The search strategy was reported previously.[@R1]

Study selection {#s2c}
---------------

In the present study, we selected only those 50 non-randomised studies on PRO that were excluded from the evaluation in the initial publication. In the study selection process, two reviewers independently judged whether a study was included or excluded. Differences were resolved by discussion without the need for a third opinion.

Data collection and analysis {#s2d}
----------------------------

The reasons for exclusion were extracted independently by two reviewers. We sought for the following data: the inclusion criteria using the PICO framework, the proportion of response of participants to questionnaires, which was required to be at least 70%, the reporting of separate baseline characteristics for each treatment group, the reporting of comparable baseline characteristics or adjustment for imbalances of these data such as the use of a Cox proportional hazard model and the reporting of statistics comparing treatment groups. Sufficient comparability was defined as a difference between baseline values that were not statistically significant. If a statistical test was not reported, we assumed two comparable values if the greater of the two values was less than 10% above the smaller one. We also required that authors reported effect measures and statistics testing the difference between treatment groups, for example, p values or effect measures including 95% CIs. Reporting of within group comparisons or before-and-after analyses was not deemed sufficient for inclusion. We did not apply a principal summary measure as we aimed to synthesise the information in a qualitative way.

Assessment of risk of bias and quality of reporting {#s2e}
---------------------------------------------------

Two reviewers independently assessed the quality of reporting of CCT according to the criteria specified in the previous paragraph. We did not specifically assess the risk of bias because we decided to exclude all papers with regard to a lack of reporting essential data.

Results {#s3}
=======

Of a total of 462 full-text articles assessed for eligibility in the previously published systematic review, 31 studies were included and 431 studies were excluded. Among the 431 excluded articles, we identified 50 non-randomised studies that were reporting on PRO ([figure 1](#BMJOPEN2013004720F1){ref-type="fig"}). We evaluated the reasons for exclusion of those 50 studies and documented the results in [table 1](#BMJOPEN2013004720TB1){ref-type="table"}. In 42% (21 of 50) studies, the essential PICO framework was simply not met. In the majority of 58% (29 of 50) studies, the predefined requirement to apply measures to contain high risk of bias was not met. Of these 29 studies, 19 reported a proportion of patients responding to questionnaires of less than 70% or did not address this item. Baseline characteristics were not presented for treatment groups in three studies. In another six studies, baseline characteristics were not comparable between treatment groups or there was no confounder control in the analysis adjusting for important different factors such as mean age. The statistical comparison between treatment groups was deemed not appropriate in one study.

###### 

Reasons for excluding PRO articles

  Non-randomised studies               Inclusion criteria   Requirements to contain high risk of bias  Comments                                
  ----------------------------------- -------------------- ------------------------------------------- ---------- ----- ----- ----- ----- ---- -------------------------------
  Bacon *et al*[@R29]                         Yes                              Yes                     No         --    --    --    --    --   No concurrent group
  Ball *et al*[@R30]                          Yes                              Yes                     No         --    --    --    --    --   Cryotherapy
  Befort *et al*[@R31]                        Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Bergman *et al*[@R32]                       Yes                              Yes                     Yes        Yes   Yes   Yes   Yes   No   No appropriate test
  Bergman *et al*[@R33]                       Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Brandeis *et al*[@R34]                      Yes                              No                      --         --    --    --    --    --   29% LDR-BT+EBRT
  Brown *et al*[@R35]                         Yes                              No                      --         --    --    --    --    --   EBRT
  Burnett *et al*[@R36]                       Yes                              Yes                     Yes        Yes   No    --    --    --   Response not reported
  Chaikin *et al*[@R37]                        No                              --                      --         --    --    --    --    --   Staging not reported
  Chen *et al*[@R38]                          Yes                              Yes                     Yes        Yes   Yes   Yes   No    --   No confounder control
  Choo *et al*[@R39]                          Yes                              Yes                     Yes        Yes   Yes   No    --    --   Baseline not reported
  Clark *et al*[@R40]                         Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Downs *et al*[@R41]                         Yes                              Yes                     Yes        Yes   Yes   Yes   No    --   No confounder control
  Eton *et al*[@R42]                          Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Frank *et al*[@R43]                         Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Fulmer *et al*[@R44]                        Yes                              Yes                     Yes        Yes   No    --    --    --   Response not reported
  Gore *et al*[@R45]                          Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Guedea *et al*[@R46]                        Yes                              Yes                     Yes        Yes   Yes   Yes   No    --   No confounder control
  Hashine *et al*[@R47]                       Yes                              Yes                     Yes        Yes   Yes   Yes   No    --   No confounder control
  Hashine *et al*[@R48]                       Yes                              Yes                     Yes        Yes   Yes   Yes   No    --   No confounder control
  Hervouet *et al*[@R49]                       No                              --                      --         --    --    --    --    --   ≥20% T3--T4 in control groups
  Hollenbeck *et al*[@R50]                    Yes                              No                      --         --    --    --    --    --   LDR-BT+EBRT
  Jo *et al*[@R51]                            Yes                              No                      --         --    --    --    --    --   High-dose rate brachytherapy
  Johnstone *et al*[@R52]                     Yes                              No                      --         --    --    --    --    --   EBRT
  Joly *et al*[@R53]                          Yes                              No                      --         --    --    --    --    --   LDR-BT+EBRT
  Kakehi *et al*[@R54]                        Yes                              Yes                     Yes        Yes   Yes   No    --    --   Baseline not reported
  Lev *et al*[@R55]                           Yes                              No                      --         --    --    --    --    --   LDR-BT+EBRT
  Lilleby *et al*[@R56]                       Yes                              No                      --         --    --    --    --    --   EBRT
  Litwin *et al*[@R57]                        Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Litwin *et al*[@R58]                        Yes                              No                      --         --    --    --    --    --   25% LDR-BT+EBRT
  Mehta *et al*[@R59]                         Yes                              Yes                     Yes        No    --    --    --    --   "Fear of cancer"\*
  Miller *et al*[@R60]                        Yes                              No                      --         --    --    --    --    --   44% LDR-BT+EBRT
  Miller *et al*[@R61]                        Yes                              Yes                     Yes        Yes   Yes   No    --    --   Baseline not reported
  Monahan *et al*[@R62]                       Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Namiki *et al*[@R63]                        Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Namiki *et al*[@R64]                        Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Ohashi *et al*[@R65]                        Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Pinkawa *et al*[@R66]                       Yes                              Yes                     No         --    --    --    --    --   LDR-BT+hormones†
  Roach *et al*[@R67]                         Yes                              No                      --         --    --    --    --    --   EBRT, single-arm trial
  Sanda *et al*[@R68]                         Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Schover *et al*[@R69]                       Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Soderdahl *et al*[@R70]                     Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Speight *et al*[@R71]                       Yes                              Yes                     Yes        Yes   No    --    --    --   Response not reported
  Stone *et al*[@R72]                         Yes                              Yes                     No         --    --    --    --    --   LDR-BT+hormones†
  Trojan *et al*[@R73]                        Yes                              Yes                     Yes        Yes   No    --    --    --   Low response
  Tward *et al*[@R74]                         Yes                              Yes                     Yes        No    --    --    --    --   Mortality differs§
  Valicenti *et al*[@R75]                     Yes                              Yes                     Yes        Yes   No    --    --    --   Response not reported
  Van de Poll- Franse *et al*[@R76]           Yes                              No                      --         --    --    --    --    --   LDR-BT+EBRT
  Wyler *et al*[@R77]                         Yes                              Yes                     Yes        Yes   Yes   Yes   No    --   No confounder control
  Zagar *et al*[@R78]                         Yes                              No                      --         --    --    --    --    --   LDR-BT+EBRT
  'NO' counts                                  2                               13                      4          2     19    3     6     1    Total: 50 studies
                                        PICO not met: 21              High risk of bias: 29                                                    

--: not appropriate.

\*Mehta *et al*[@R59]: no appropriate endpoint.

†Pinkawa *et al*[@R66]; Stone *et al*[@R72]: neoadjuvant hormonal therapy.

§Tward *et al*[@R74]: non-disease-related mortality differs greatly.C, comparison of interest is radical prostatectomy, external beam radiotherapy, or no primary therapy; EBRT, external beam radiotherapy; I, intervention of interest is low-dose rate brachytherapy as monotherapy; LDR-BT, permanent interstitial low-dose rate brachytherapy; O, outcome of interest is function, bother, or generic health-related quality of life; P, patients with localised prostate cancer; PRO, patient-reported outcomes.

![Study flow. PICO: population, intervention, comparator, outcome; PRO: patient-reported outcomes; RCT: randomised controlled trial.](bmjopen2013004720f01){#BMJOPEN2013004720F1}

Discussion {#s4}
==========

Main results {#s4a}
------------

In summary, we found that roughly 4 of 10 excluded PRO studies did not meet the essential inclusion criteria using the PICO framework. This result is consistent with the problem of information retrieval aiming at a high recall and ending up with a low precision. The papers were obviously not relevant to the research question and we did not further examine the quality of reporting. We also found that roughly 6 of 10 excluded PRO studies met the PICO framework but did not provide the predefined requirements to care sufficiently enough for a low response of patients to questionnaires, for reporting baseline characteristics between treatment groups, for adjusting differences in those baseline characteristics between treatment groups and to use appropriate statistics to compare the outcome between treatment groups.

Quality of reporting of PROs {#s4b}
----------------------------

We identified a lack in the quality of reporting in many excluded CCT and wish to stress the importance of considering a series of requirements while conducting a study on PRO. Other authors have reported recently that, concerning disease-specific mortality or disease-free survival, the available studies did not show significant differences between treatment groups.[@R13] [@R14] In the view of unknown or small differences in survival measures, the results of PRO studies could have a noticeable impact on medical decision-making.[@R15] [@R16] None of the 50 excluded studies reported a non-responder analysis, although it is known that non-responders may have different attitudes than responders. Etter and Perneger[@R17] concluded that low response rates may be associated with overestimating an effect and that the strength and direction of a non-response bias may depend on the mechanism of non-response. Therefore, results may be confounded if the proportion of included data not available for analysis such as data from non-responders or due to loss to follow-up is considerable. We believe that a value of 30% or more can be denoted as considerable. Lowering this threshold, for example, to 20%, would have resulted in less included studies. However, others suggested that 20% or more loss would be sufficient for a high risk of bias threatening the validity of results.[@R18] Concerning questionnaires, we recommend taking measures that are known to improve response rates.[@R19] [@R20] Edwards[@R21] conducted a systematic review to identify effective strategies to increase the response to postal and electronic questionnaires. The authors found several strategies to increase the response, for example, prenotification, follow-up contact, shorter questionnaires, mentioning an obligation to respond, university sponsorship, non-monetary incentives, a statement that others had responded, an offer of survey results, giving a deadline. We did not use a strict algorithm to differentiate between comparable and not comparable baseline values between treatment groups. A statistically significant difference was judged as not comparable. Non-significant differences were also regarded as not comparable if the difference was at least 10% of the lower of two values. Using this approach we tried to reduce subjective decisions. We are not aware of published strict algorithms in this matter.

High risk of bias inherent in non-RCTs {#s4c}
--------------------------------------

With a view to include only one RCT, the initial publication was based almost exclusively on CCT. However, the lack of randomisation poses a very large challenge to the authors who are advised to deal with essential problems such as selection bias and confounding. Otherwise, the findings may not be valid and of limited usefulness and the many efforts may be in vain. We wish to stress that the non-randomised design is associated with a high risk of bias because known and unknown characteristics may be distributed unequally between groups.[@R22] Certain study characteristics, such as prospective design, concurrent control group, adjustment of results with respect to different baseline values and confounder control, can limit additional bias. For example, Ioannidis *et al*[@R23] reported that discrepancies between RCT and CCT were less common when only CCT with a prospective design were considered. The Cochrane Collaboration offers a guide for inclusion of non-randomised studies[@R24] and it has developed a tool for assessing the risk of bias in RCT and CCT.[@R25] Guidelines for reporting observational studies have been published to improve their quality.[@R5] Cox regression analysis, propensity-score-based analysis and instrumental variable analysis are methods that have been used for correction of confounding bias in non-randomised studies.[@R26] Different values of various outcome measures between groups may be simply caused by different baseline data in lieu of absent significant treatment effects. We accepted any type of method adjusting or stratifying for one or more known differences in baseline characteristics. Nevertheless, it should be kept in mind that methods of adjustment do not guarantee removal of bias and that residual confounding may remain high.[@R22] Concerning the non-randomised design, we strongly recommend the use of methods for adjusting the results for confounders to aim for a less-biased estimation of the treatment effect[@R27] and the adoption of guidelines for the reporting of observational studies.[@R5]

Strengths and limitations {#s4d}
-------------------------

The strengths of the present study are a comprehensive literature search, strict adherence to the projected methodology, the identification of a lack of quality in PRO studies and addressing the specific problems of PRO studies. We should consider some limitations: the study is confined to a single disease, so conclusions drawn from its results may not be generalisable to other diseases. The arbitrary limits set for inclusion of studies are responsible for the extent of excluded studies. These limits may be questioned by other investigators. During the re-evaluation of study quality, we found that one study fulfilled all criteria, although, this study was excluded in previous reports.[@R28] The minimum follow-up of 70% for inclusion was set arbitrarily and others might find this threshold too low. We did not endorse the recently published reporting of PRO in randomised trials, an extension of the CONSORT statement.[@R4] All included studies in the present review are non-randomised. We think that the lack of randomisation is the prevailing issue. We did not endorse the CONSORT PRO extension for another reason. The included studies were published many years before this extension was published. There might be a need to develop an extension of the STROBE statement[@R5] with the aim of improving the reporting of PRO in non-randomised studies. This extension could emphasise the specific challenges of reporting PRO with respect to lack of randomisation.

Conclusions {#s5}
===========

We found that a considerable number of non-randomised controlled reporting PROs were excluded from a systematic review because of a lack of predefined reporting requirements. The assumed overall risk of bias was regarded as too high to consider the data of these studies for inclusion in the systematic review. With respect to the reporting of PROs, active efforts are required to improve the quality of reporting in non-randomised controlled trials and to increase the number of randomised controlled trials.
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